H

Hrangdanglien

Active Director Director DIN 08458016
DIN 08458016 First appointment May 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since May 2019
Shareholding value •••• Premium profile

About Hrangdanglien

Data last updated:

Hrangdanglien is a Director at Zenzi Pharmaceutical Industries Private Limited (since 2019), Director at Alpha-Pharma Healthcare Private Limited (since 2019) and Director at Meghdoot Chemicals Limited (since 2019), and holds 2 more current directorships. The companies operate in Pharma and Chemicals. The 5 current companies with reported revenue have a combined latest revenue of ₹48.51 Cr; the largest is Zenzi Pharmaceutical Industries Private Limited at ₹26.29 Cr (FY 2025). Earlier, Hrangdanglien was an Additional Director at Moirae Generics Private Limited (2019).

DIN 08458016
Primary Designation Director
Industry Pharma
First Appointment 22 May 2019
Oldest Company Age 56 yrs
Largest company Zenzi Pharmaceutical Industries Private Limited · ₹26.29 Cr (FY 2025)
Combined revenue ₹48.51 Cr across 5 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director22 May 20192005₹26.29 Cr (FY 2025)Active
Director27 May 20192014₹20.96 Cr (FY 2025)Active
Meghdoot Chemicals Limited U24110MH1970PLC014768
Director22 May 20191970₹1.26 Cr (FY 2025)Active
Unigen Life Sciences Private Limited U24297MH2013FTC239278
Director22 May 20192013₹7,130 (FY 2025)Active
Coin Pharmaceuticals Private Limited U24232MH2012PTC232068
Director22 May 20192012₹5,000 (FY 2016)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Moirae Generics Private Limited U51909DL2010FTC198694
Additional Director22 May 20192010₹51,235 (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Hrangdanglien

Directorship timeline

Open interactive timeline →
Meghdoot Chemicals Limited
Zenzi Pharmaceutical Industries Private Limited
Coin Pharmaceuticals Private Limited
Unigen Life Sciences Private Limited
Premium access

Shareholding and investment profile for Hrangdanglien

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hrangdanglien

Hrangdanglien currently holds 5 directorships: Zenzi Pharmaceutical Industries Private Limited (Director, since 22 May 2019, revenue ₹26.29 Cr (FY 2025)); Alpha-Pharma Healthcare Private Limited (Director, since 27 May 2019, revenue ₹20.96 Cr (FY 2025)); Meghdoot Chemicals Limited (Director, since 22 May 2019, revenue ₹1.26 Cr (FY 2025)); Unigen Life Sciences Private Limited (Director, since 22 May 2019, revenue ₹7,130 (FY 2025)); Coin Pharmaceuticals Private Limited (Director, since 22 May 2019, revenue ₹5,000 (FY 2016)).

Hrangdanglien was first appointed on 22 May 2019 as Director at Zenzi Pharmaceutical Industries Private Limited.

The 5 current companies of Hrangdanglien that report revenue have a combined latest revenue of ₹48.51 Cr: Zenzi Pharmaceutical Industries Private Limited ₹26.29 Cr (FY 2025); Alpha-Pharma Healthcare Private Limited ₹20.96 Cr (FY 2025); Meghdoot Chemicals Limited ₹1.26 Cr (FY 2025); Unigen Life Sciences Private Limited ₹7,130 (FY 2025); Coin Pharmaceuticals Private Limited ₹5,000 (FY 2016).

Hrangdanglien held 1 earlier board appointment: Moirae Generics Private Limited (Additional Director, 22 May 2019 to 16 Sep 2019).

The current boards of Hrangdanglien's companies include Jacob Sporon Fiedler (Zenzi Pharmaceutical Industries Private Limited), Pratik Harshad Kalsariya (Meghdoot Chemicals Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available